1. Pink Sheet
  2. >>Geography

Nasacort, Flonase Competition Heats Up As Sanofi Appeals NAD Review

 
• By Eileen Francis

Chattem appeals a National Advertising Division decision from a review of advertising comparing its Nasacort nasal allergy spray to GSK’s Flonase. The Sanofi business maintains NAD relied on a “cookbook” approach to determine whether claims for the product are substantiated.

The competition for OTC intranasal corticosteroid market share that plays out in frequent comparative-claim advertising by NasacortAllergy 24HR and Flonase Allergy Relief continues in the industry self-regulation arena.

Sanofi’s U.S. consumer health care product business, Chattem Inc

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from United States

More from North America